BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 28639285)

  • 1. Porphyrin modified trastuzumab improves efficacy of HER2 targeted photodynamic therapy of gastric cancer.
    Korsak B; Almeida GM; Rocha S; Pereira C; Mendes N; Osório H; Pereira PMR; Rodrigues JMM; Schneider RJ; Sarmento B; Tomé JPC; Oliveira C
    Int J Cancer; 2017 Oct; 141(7):1478-1489. PubMed ID: 28639285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular targeted photoimmunotherapy for HER2-positive human gastric cancer in combination with chemotherapy results in improved treatment outcomes through different cytotoxic mechanisms.
    Ito K; Mitsunaga M; Arihiro S; Saruta M; Matsuoka M; Kobayashi H; Tajiri H
    BMC Cancer; 2016 Jan; 16():37. PubMed ID: 26810644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination photoimmunotherapy with monoclonal antibodies recognizing different epitopes of human epidermal growth factor receptor 2: an assessment of phototherapeutic effect based on fluorescence molecular imaging.
    Ito K; Mitsunaga M; Nishimura T; Kobayashi H; Tajiri H
    Oncotarget; 2016 Mar; 7(12):14143-52. PubMed ID: 26909859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strengthening Gastric Cancer Therapy by Trastuzumab-Conjugated Nanoparticles with Simultaneous Encapsulation of Anti-MiR-21 and 5-Fluorouridine.
    Hu N; Yin JF; Ji Z; Hong Y; Wu P; Bian B; Song Z; Li R; Liu Q; Wu F
    Cell Physiol Biochem; 2017; 44(6):2158-2173. PubMed ID: 29241186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trastuzumab Inhibits Growth of HER2-Negative Gastric Cancer Cells Through Gastrin-Initialized CCKBR Signaling.
    Cui Y; Li SB; Peng XC; Wu J; Fu GH
    Dig Dis Sci; 2015 Dec; 60(12):3631-41. PubMed ID: 26173505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer.
    Barok M; Tanner M; Köninki K; Isola J
    Cancer Lett; 2011 Jul; 306(2):171-9. PubMed ID: 21458915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment.
    An E; Ock CY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Liao WL; Cecchi F; Blackler A; Thyparambil S; Kim WH; Burrows J; Hembrough T; Catenacci DVT; Oh DY; Bang YJ
    Ann Oncol; 2017 Jan; 28(1):110-115. PubMed ID: 27687309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment of a Patient-derived Xenograft for Development of Personalized HER2-targeting Therapy in Gastric Cancer.
    Shin SH; Park SS; Ju EJ; Park J; Ko EJ; Hwang JJ; Suh YA; Jang SJ; Lee JS; Ko BK; Kim KT; Lee JS; Song SY; Jeong SY; Choi EK
    Anticancer Res; 2018 Jan; 38(1):287-293. PubMed ID: 29277785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-nanoparticle conjugate constructed with trastuzumab and nanoparticle albumin-bound paclitaxel for targeted therapy of human epidermal growth factor receptor 2-positive gastric cancer.
    Xiong J; Han S; Ding S; He J; Zhang H
    Oncol Rep; 2018 Mar; 39(3):1396-1404. PubMed ID: 29328489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multifunctional trastuzumab-chlorin e6 conjugate for the treatment of HER2-positive human breast cancer.
    Kim KS; Kim J; Kim DH; Hwang HS; Na K
    Biomater Sci; 2018 May; 6(5):1217-1226. PubMed ID: 29578555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model.
    Yamashita-Kashima Y; Shu S; Harada N; Fujimoto-Ouchi K
    Oncol Rep; 2013 Sep; 30(3):1087-93. PubMed ID: 23783223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dicer increases the indication for trastuzumab treatment in gastric cancer patients via overexpression of human epidermal growth factor receptor 2.
    Wu J; Zhao Q; Zhao Y; Zhang X; Tian Y; Guo Z
    Sci Rep; 2021 Mar; 11(1):6993. PubMed ID: 33772068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab-based near-infrared photoimmunotherapy in xenograft mouse of breast cancer.
    Yamashita S; Kojima M; Onda N; Yoshida T; Shibutani M
    Cancer Med; 2023 Feb; 12(4):4579-4589. PubMed ID: 36259134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models.
    Yamashita-Kashima Y; Iijima S; Yorozu K; Furugaki K; Kurasawa M; Ohta M; Fujimoto-Ouchi K
    Clin Cancer Res; 2011 Aug; 17(15):5060-70. PubMed ID: 21700765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of B7-H3 and HER2 co-expression and therapeutic value of combination treatment in gastric cancer.
    Shao X; Zhan S; Quan Q; Shen Y; Chen S; Zhang X; Li R; Liu M; Cao L
    Int Immunopharmacol; 2022 Sep; 110():108988. PubMed ID: 35777267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer.
    Zhu Y; Tian T; Zou J; Wang Q; Li Z; Li Y; Liu X; Dong B; Li N; Gao J; Shen L
    BMC Cancer; 2015 Nov; 15():894. PubMed ID: 26560145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The anti-HER3 antibody in combination with trastuzumab exerts synergistic antitumor activity in HER2-positive gastric cancer.
    Wang Q; Zhang X; Shen E; Gao J; Cao F; Wang X; Li Y; Tian T; Wang J; Chen Z; Wang J; Shen L
    Cancer Lett; 2016 Sep; 380(1):20-30. PubMed ID: 27317872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.
    Liu YJ; Shen D; Yin X; Gavine P; Zhang T; Su X; Zhan P; Xu Y; Lv J; Qian J; Liu C; Sun Y; Qian Z; Zhang J; Gu Y; Ni X
    Br J Cancer; 2014 Mar; 110(5):1169-78. PubMed ID: 24518603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor Heterogeneity in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Assessed by CT Texture Analysis: Association with Survival after Trastuzumab Treatment.
    Yoon SH; Kim YH; Lee YJ; Park J; Kim JW; Lee HS; Kim B
    PLoS One; 2016; 11(8):e0161278. PubMed ID: 27517841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathologic Response of HER2-positive Gastric Cancer to Trastuzumab-based Chemotherapy.
    Urabe M; Ushiku T; Seto Y; Fukayama M
    Am J Surg Pathol; 2016 Oct; 40(10):1326-33. PubMed ID: 27259008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.